Key Takeaways
- • KKR has completed its acquisition of Integer Holdings, a Plano, Texas-based contract developer and manufacturer of medical devices, at an enterprise value of about $5.7 billion.
- • The deal equates to about 14.2x Integer's 2025 adjusted EBITDA of $402 million, on 2025 sales of $1.9 billion (up 8% from 2024).
- • The investment was made through KKR's core private equity strategy, using equity from KKR-managed funds and committed debt, with KKR planning an employee ownership program at Integer.
- • Medtech private equity buyout value nearly doubled to an estimated $33 billion in 2025, with deal count up nearly 20% to about 88 transactions, according to Bain & Company.
- • Integer, led by President and CEO Payman Khales, employs about 11,000 people and supplies components and finished devices for pacemakers, defibrillators, catheters and neuromodulation systems.
Summary
Internally, Integer generated $1.9 billion of sales in 2025, up 8% from 2024, and adjusted EBITDA of $402 million, up 12%. The enterprise value implies a multiple of about 14.2x 2025 adjusted EBITDA. KKR funded the transaction through its core private equity strategy, using equity from KKR-managed funds and committed debt. Citi, KKR Capital Markets, Barclays, UBS and Jefferies were lead arrangers of the debt financing. Goldman Sachs advised Integer, while Centerview Partners, Barclays, Citi and Raymond James advised KKR.
Integer's lineage traces to Wilson Greatbatch, who designed an implantable pacemaker in 1958 and patented it in 1962. Wilson Greatbatch Technologies listed on the New York Stock Exchange in September 2000, raising $80 million. In 2014, Accellent, a medical device contract manufacturer backed by KKR and Bain Capital, acquired Lake Region Medical and adopted its name. Greatbatch bought the combined business in 2015 at an enterprise value of approximately $1.8 billion and renamed itself Integer Holdings in 2016.
KKR plans to establish an employee ownership program at Integer, consistent with its practice at more than 90 portfolio companies since 2011. Max Lin, a KKR partner, described Integer as an exceptional platform with differentiated capabilities, a track record for quality and reliability, and attractive, durable end-markets. Payman Khales said the company is well positioned to accelerate its growth strategy with KKR. According to Bain & Company, medtech buyout value nearly doubled to an estimated $33 billion in 2025, and healthcare private equity deal value reached a record $191 billion. Bain attributes medtech interest to revenue growth, higher margins and multiple expansion, and Integer's broad customer base spreads its exposure across customers and product lines. KKR was founded in 1976 and is headquartered in New York City.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.